IGF-I Lr3 is significantly more potent (2-3x) than IGF-I in studies, because it has a lower affinity to be rendered inactive by IGF binding proteins
Final Thoughts AOD-9604, semaglutide, and tirzepatide all live in metabolic research, but they're three different tools for three different questions: direct adipose lipolysis versus single- and dual-incretin signaling
Thus, given the particularities of the observed BPC 157 therapy effect [1,2,3,4,5,6,7,8,9,10,11,15,27,28,29,30,33,109,124,125], this final point, the equation between the exogenous effects and endogenous presence to verify endogenous presence and significance, can be a suggestive argument for the possible BPC 157/neurotransmitter relation
It gets labeled as anxiety, disorganization, or just being too much, and we carry that for years without realizing there might be more going on
Furthermore, quercetin directly targets and inhibits NLRP3 inflammasome activation